Literature DB >> 23288796

Bipolar radiofrequency-induced interstitial thermoablation for oral cavity vascular malformations: Preliminary results in a series of 5 children.

Senol Civelek1, Ibrahim Sayın, Ibrahim Ercan, Burak Omür Cakır, Suat Turgut.   

Abstract

We report our assessment of the effectiveness of bipolar radiofrequency-induced interstitial thermoablation (BRIT) for the treatment of certain oral cavity vascular malformations in 5 children. Two of these patients had lymphangiomatous macroglossia (LM), 1 had lymphangioma circumscriptum (LC), and 2 had a venous malformation (VM). Each patient underwent BRIT at least twice; treatment was delivered at 4- to 8-week intervals according to each patient's circumstances. The 2 patients with LM required three treatment sessions; although their tongue volume decreased after each session, both still required a partial glossectomy to achieve a satisfactory reduction in volume. The patient with LC underwent two BRIT treatments, which reduced the size of the lesion by half; the remainder was excised. The 2 patients with a VM (1 buccal and 1 lingual) responded well to BRIT, and their malformations almost completely disappeared. Our early results with BRIT suggest that it is an effective treatment for oral cavity vascular malformations-more so for patients with venous rather than lymphangiomatous lesions.

Entities:  

Mesh:

Year:  2012        PMID: 23288796     DOI: 10.1177/014556131209101111

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  2 in total

Review 1.  Pediatric lymphatic malformations: evolving understanding and therapeutic options.

Authors:  Ann M Defnet; Naina Bagrodia; Sonia L Hernandez; Natalie Gwilliam; Jessica J Kandel
Journal:  Pediatr Surg Int       Date:  2016-01-27       Impact factor: 1.827

2.  Curative effects of RF combined with DSA-guided ethanol sclerotherapy in venous malformations.

Authors:  Xing Wang; Jian Meng; Jie Zhang; Ruihan Wu; Jianmin Gu; Cuiling Shao; Kun Han
Journal:  Exp Ther Med       Date:  2016-10-13       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.